Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lumena Pharmaceuticals

Shire Basingstoke

Shire faces $650m loss on Dermagraft sale

Sells struggling foot ulcer treatment to Organogenesis

Sanofi reception

Sanofi strikes $700m rare diseases deal

Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs

- PMLiVE

ABPI reprimands for four pharma firms

Allergan, Shire Pharmaceuticals, Gedeon Richter and Sanofi breach Code of Practice

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

- PMLiVE

EMA: more fee reductions for orphan drugs

Greater incentives introduced for larger companies

The logistics of orphan drugs

Managing a rare disease global access programme, the goal is to minimise risk and get the drug to the patient on time

- PMLiVE

Rare disease strategy for the UK launched

Aims to improve understanding and boost research

Shire Basingstoke

Shire snaps up Viropharma to build $2bn rare disease unit

Gains access to Cinryze in expensive but 'strategically sound' deal

Shire Basingstoke

Shire mulls UK job cuts

Enters “employee consultation process” for research site in Basingstoke

- PMLiVE

Orphan status for Stem Cell’s leukaemia drug

Tigecycline wins FDA rare disease designation

Shire appoints finance-focused board member

Dominic Blakemore is group finance director of Compass Group

- PMLiVE

FDA sets up rare disease research fund

Will invest $14m across 15 orphan drug projects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links